{"transactions":[{"id":4633321,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":1416,"price":85.8855,"value":121613.868,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.82 to $85.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":20191214,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633320,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":84,"price":85.8855,"value":7214.382,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.82 to $85.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1669727,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633319,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":20031,"price":85.403,"value":1710707.493,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.16 to $85.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":20189798,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633318,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":1195,"price":85.403,"value":102056.585,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.16 to $85.99, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1669643,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633317,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":10381,"price":84.2421,"value":874517.2401,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.81 to $84.65, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":20169767,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633316,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-29","kind":"purchase","planned":false,"acquired":true,"shares":619,"price":84.2421,"value":52145.8599,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.81 to $84.65, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1668448,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633315,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":196608,"price":89.8555,"value":17666310.144,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.11 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":20159386,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633314,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":11729,"price":89.8555,"value":1053915.1595,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.11 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1667829,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633313,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":82673,"price":89.6036,"value":7407798.4228,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.32 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19962778,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633312,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4932,"price":89.6036,"value":441924.9552,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $89.32 to $90.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1656100,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633311,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":107772,"price":88.646,"value":9553556.712,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.01 to $89.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19880105,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633310,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":6428,"price":88.646,"value":569816.488,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.01 to $89.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1651168,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633309,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":98561,"price":88.5671,"value":8729261.9431,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.25 to $88.97, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19772333,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633308,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":5880,"price":88.5671,"value":520774.548,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $88.25 to $88.97, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1644740,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633307,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":75176,"price":87.5065,"value":6578388.644,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $87.03 to $88.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19673772,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633306,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4485,"price":87.5065,"value":392466.6525,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $87.03 to $88.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1638860,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633305,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":63539,"price":86.9421,"value":5524214.0919,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.465, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19598596,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633304,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":3790,"price":86.9421,"value":329510.559,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.465, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1634375,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633303,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":16036,"price":86.8142,"value":1392152.5112,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19535057,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633302,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":957,"price":86.8142,"value":83081.1894,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $86.47 to $87.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1630585,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633301,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":3114,"price":86.7217,"value":270051.3738,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $86.70 to $86.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19519021,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633300,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:31:11.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":186,"price":86.7217,"value":16130.2362,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $86.70 to $86.75, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1629628,"source":{"system":"sec-edgar","filing":"0001193125-26-409127","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409127/ownership.xml","form_type":"4"}},{"id":4633354,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":38932,"price":85.9656,"value":3346812.7392,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.50 to $86.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19515907,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633353,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2322,"price":85.9656,"value":199612.1232,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $85.50 to $86.47, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1629442,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633352,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":109842,"price":84.8543,"value":9320566.0206,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $84.41 to $85.40, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19476975,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633351,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":6553,"price":84.8543,"value":556050.2279,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $84.41 to $85.40, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1627120,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633350,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":123888,"price":83.9512,"value":10400546.2656,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.39 to $84.39, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19367133,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633349,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":7390,"price":83.9512,"value":620399.368,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $83.39 to $84.39, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1620567,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633348,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":19554,"price":83.1552,"value":1626016.7808,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.66 to $83.38, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19243245,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633347,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1167,"price":83.1552,"value":97042.1184,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.66 to $83.38, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1613177,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633346,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1699,"price":82.6822,"value":140477.0578,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.52 to $82.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19223691,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633345,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":101,"price":82.6822,"value":8350.9022,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $82.52 to $82.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1612010,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633344,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":651,"price":81.915,"value":53326.665,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19221992,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633343,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":39,"price":81.915,"value":3194.685,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1611909,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633342,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":28028,"price":81.8162,"value":2293144.4536,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.27 to $82.22, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19221341,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633341,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1672,"price":81.8162,"value":136796.6864,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.27 to $82.22, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1611870,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633340,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":17490,"price":81.3139,"value":1422180.111,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.31 to $81.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19193313,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633339,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1044,"price":81.3139,"value":84891.7116,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $81.31 to $81.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1610198,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633338,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":5654,"price":81.2019,"value":459115.5426,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.935 to $81.73, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19175823,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633337,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":338,"price":81.2019,"value":27446.2422,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.935 to $81.73, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1609154,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633336,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":17159,"price":81.0204,"value":1390229.0436,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.455 to $81.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19170169,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633335,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1024,"price":81.0204,"value":82964.8896,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.455 to $81.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1608816,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633334,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1027,"price":80.52,"value":82694.04,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19153010,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633333,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":61,"price":80.52,"value":4911.72,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1607792,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633332,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":6783,"price":80.2259,"value":544172.2797,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.00 to $80.79, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19151983,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633331,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":404,"price":80.2259,"value":32411.2636,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $80.00 to $80.79, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1607731,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633330,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":14827,"price":79.7076,"value":1181824.5852,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $79.44 to $80.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19145200,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633329,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":884,"price":79.7076,"value":70461.5184,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $79.44 to $80.00, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1607327,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633328,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":283,"price":79.63,"value":22535.29,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19130373,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633327,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":17,"price":79.63,"value":1353.71,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1606443,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633326,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":8956,"price":79.4045,"value":711146.702,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $79.07 to $79.55, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19130090,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633325,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:30:05.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":534,"price":79.4045,"value":42402.003,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $79.07 to $79.55, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1606426,"source":{"system":"sec-edgar","filing":"0001193125-26-409118","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409118/ownership.xml","form_type":"4"}},{"id":4633424,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":49771,"price":78.5681,"value":3910412.9051,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $77.92 to $78.91, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19121134,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633423,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2969,"price":78.5681,"value":233268.6889,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $77.92 to $78.91, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1605892,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633422,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":48350,"price":77.4314,"value":3743808.19,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $76.94 to $77.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19071363,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633421,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2884,"price":77.4314,"value":223312.1576,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $76.94 to $77.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1602923,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633420,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":61700,"price":76.345,"value":4710486.5,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $75.88 to $76.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":19023013,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633419,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":3681,"price":76.345,"value":281025.945,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $75.88 to $76.88, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1600039,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633418,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":32261,"price":75.5151,"value":2436192.6411,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $74.88 to $75.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18961313,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633417,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1924,"price":75.5151,"value":145291.0524,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $74.88 to $75.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1596358,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633416,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":76723,"price":73.9686,"value":5675092.8978,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $73.88 to $74.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18929052,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633415,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4577,"price":73.9686,"value":338554.2822,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $73.88 to $74.86, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1594434,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633414,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":78726,"price":73.0777,"value":5753115.0102,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $72.77 to $73.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18852329,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633413,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4696,"price":73.0777,"value":343172.8792,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $72.77 to $73.77, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1589857,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633412,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":278978,"price":72.3873,"value":20194464.1794,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $71.77 to $72.765, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18773603,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633411,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":16641,"price":72.3873,"value":1204597.0593,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $71.77 to $72.765, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1585161,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633410,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":17698,"price":71.4843,"value":1265129.1414,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $70.80 to $71.76, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18494625,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633409,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":1056,"price":71.4843,"value":75487.4208,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $70.80 to $71.76, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1568520,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633408,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":39066,"price":68.9578,"value":2693905.4148,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.65 to $69.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18476927,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633407,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2331,"price":68.9578,"value":160740.6318,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.65 to $69.52, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1567464,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633406,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2585,"price":68.3736,"value":176745.756,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.28 to $68.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18437861,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633405,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":154,"price":68.3736,"value":10529.5344,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $68.28 to $68.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1565133,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633404,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":5382,"price":67.0967,"value":361114.4394,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $66.86 to $67.23, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18435276,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633403,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":321,"price":67.0967,"value":21538.0407,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $66.86 to $67.23, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1564979,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633402,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":8021,"price":64.4276,"value":516773.7796,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $63.72 to $64.66, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18429894,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633401,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":479,"price":64.4276,"value":30860.8204,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $63.72 to $64.66, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1564658,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633400,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":4067,"price":62.9623,"value":256067.6741,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $62.48 to $63.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18421873,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633399,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":243,"price":62.9623,"value":15299.8389,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $62.48 to $63.46, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1564179,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633398,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":44690,"price":61.6252,"value":2754030.188,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $61.44 to $62.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18417806,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633397,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":2666,"price":61.6252,"value":164292.7832,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were traded by 667 and Life Sciences in multiple transactions at prices ranging from $61.44 to $62.43, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1563936,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633396,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":14344,"price":61.2104,"value":878001.9776,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $60.50 to $61.42, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":18373116,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":4633395,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-10-01T00:29:20.000Z","date":"2026-09-28","kind":"purchase","planned":false,"acquired":true,"shares":856,"price":61.2104,"value":52396.1024,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares of common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") were traded by 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") in multiple transactions at prices ranging from $60.50 to $61.42, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the \"Staff\"), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Common Stock reported in column 5 of Table I held directly by 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held directly by the Funds. Baker Bros. Advisors (GP) LLC (the \"Adviser GP\") is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held directly by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held directly by the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."}],"balance_after":1561270,"source":{"system":"sec-edgar","filing":"0001193125-26-409116","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526409116/ownership.xml","form_type":"4"}},{"id":706786,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:40:17.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":66500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-forty-eighth (1/48th) of the shares vest one month after July 1, 2026; the balance of the shares vest in a series of forty-seven (47) successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 Equity Incentive Plan) as of each vesting date."}],"balance_after":66500,"derivative":{"exercise_price":42.42,"expiration_date":"2036-07-14","underlying":"Common Stock","underlying_shares":66500},"source":{"system":"sec-edgar","filing":"0001754045-26-000008","document":"form4-07172026_080713.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000008/form4-07172026_080713.xml","form_type":"4"}},{"id":706892,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29764,"kind":"person","name":"PERLROTH VICTOR","position":1,"cik":"0001754181","reported_name":"PERLROTH VICTOR","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Chairman and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-17T20:38:32.000Z","date":"2026-07-15","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-forty-eighth (1/48th) of the shares vest one month after July 1, 2026; the balance of the shares vest in a series of forty-seven (47) successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 Equity Incentive Plan) as of each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":42.42,"expiration_date":"2036-07-14","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001754181-26-000011","document":"form4-07172026_080728.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1754181/000175418126000011/form4-07172026_080728.xml","form_type":"4"}},{"id":717828,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":17298,"kind":"person","name":"Yang Taiyin","position":1,"cik":"0001334505","reported_name":"Yang Taiyin","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:58:29.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":17731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date."}],"balance_after":17731,"derivative":{"exercise_price":38.96,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":17731},"source":{"system":"sec-edgar","filing":"0001334505-26-000002","document":"form4-07022026_090725.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000133450526000002/form4-07022026_090725.xml","form_type":"4"}},{"id":718825,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":33117,"kind":"person","name":"PROFUSEK ROBERT","position":1,"cik":"0001143732","reported_name":"PROFUSEK ROBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:57:10.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":17731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date."}],"balance_after":17731,"derivative":{"exercise_price":38.96,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":17731},"source":{"system":"sec-edgar","filing":"0001143732-26-000002","document":"form4-07022026_090706.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1143732/000114373226000002/form4-07022026_090706.xml","form_type":"4"}},{"id":717827,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":26662,"kind":"person","name":"Levy Richard S","position":1,"cik":"0001454983","reported_name":"Levy Richard S","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:55:34.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":17731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date."}],"balance_after":17731,"derivative":{"exercise_price":38.96,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":17731},"source":{"system":"sec-edgar","filing":"0001454983-26-000006","document":"form4-07022026_090730.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000145498326000006/form4-07022026_090730.xml","form_type":"4"}},{"id":717826,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":32815,"kind":"person","name":"Dahiyat Bassil I","position":1,"cik":"0001591312","reported_name":"Dahiyat Bassil I","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:54:02.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":17731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date."}],"balance_after":17731,"derivative":{"exercise_price":38.96,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":17731},"source":{"system":"sec-edgar","filing":"0001591312-26-000006","document":"form4-07022026_090759.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000159131226000006/form4-07022026_090759.xml","form_type":"4"}},{"id":717842,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":15856,"kind":"person","name":"Bancroft Charles A","position":1,"cik":"0001480250","reported_name":"Bancroft Charles A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T21:52:09.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":17731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date."}],"balance_after":17731,"derivative":{"exercise_price":38.96,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":17731},"source":{"system":"sec-edgar","filing":"0001480250-26-000003","document":"form4-07022026_090705.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1480250/000148025026000003/form4-07022026_090705.xml","form_type":"4"}},{"id":719143,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-07-02T20:32:36.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":17731,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 17,731 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\"), on June 30, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Equity Incentive Plan. The Stock Options have a strike price of $38.96 per share, and vest on the earlier of the first anniversary of the grant date or one day prior to the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 17,731 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\"), on June 30, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Equity Incentive Plan. The Stock Options have a strike price of $38.96 per share, and vest on the earlier of the first anniversary of the grant date or one day prior to the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Felix J. Baker serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Felix J. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Felix J. Baker of 17,731 Stock Options on Table II. This grant of 17,731 Stock Options for Felix J. Baker is reported for each of the Funds as each has an indirect pecuniary interest in such securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences."}],"balance_after":17731,"derivative":{"exercise_price":38.96,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":17731},"source":{"system":"sec-edgar","filing":"0001193125-26-294724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526294724/ownership.xml","form_type":"4"}},{"id":719142,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":24760,"kind":"person","name":"BAKER BROS. ADVISORS LP","position":1,"cik":"0001263508","reported_name":"BAKER BROS. ADVISORS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24762,"kind":"person","name":"667, L.P.","position":2,"cik":"0001551139","reported_name":"667, L.P.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24761,"kind":"person","name":"Baker Bros. Advisors (GP) LLC","position":3,"cik":"0001580575","reported_name":"Baker Bros. Advisors (GP) LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24763,"kind":"person","name":"Baker Brothers Life Sciences LP","position":4,"cik":"0001363364","reported_name":"Baker Brothers Life Sciences LP","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24764,"kind":"person","name":"BAKER FELIX","position":5,"cik":"0001087940","reported_name":"BAKER FELIX","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24765,"kind":"person","name":"BAKER JULIAN","position":6,"cik":"0001087939","reported_name":"BAKER JULIAN","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Non-Qualified Stock Options (right to buy)","published_at":"2026-07-02T20:32:36.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":17731,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnotes"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 17,731 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\"), on June 30, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Equity Incentive Plan. The Stock Options have a strike price of $38.96 per share, and vest on the earlier of the first anniversary of the grant date or one day prior to the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2036."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Includes 17,731 non-qualified stock options (\"Stock Options\") exercisable solely into common stock (\"Common Stock\") of Kodiak Sciences Inc. (the \"Issuer\") granted by the Issuer to Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the \"Adviser GP\"), on June 30, 2026, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Equity Incentive Plan. The Stock Options have a strike price of $38.96 per share, and vest on the earlier of the first anniversary of the grant date or one day prior to the date of the next annual meeting of stockholders of the Issuer, subject to Felix J. Baker's continued service on the board of directors of the Issuer (the \"Board\") through the vesting date. The Stock Options expire on June 29, 2036."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Felix J. Baker serves on the Board as a representative of 667, L.P. (\"667\") and Baker Brothers Life Sciences, L.P. (\"Life Sciences\", and together with 667, the \"Funds\") and their affiliates and control persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Baker Bros. Advisors LP (the \"Adviser\") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Pursuant to the policies of the Adviser, Felix J. Baker does not have a right to any of the Issuer's securities issued as compensation for his service on the Board, and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The acquisition of Stock Options reported on this form represents a single grant to Felix J. Baker of 17,731 Stock Options on Table II. This grant of 17,731 Stock Options for Felix J. Baker is reported for each of the Funds as each has an indirect pecuniary interest in such securities."}],"balance_after":17731,"derivative":{"exercise_price":38.96,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":17731},"source":{"system":"sec-edgar","filing":"0001193125-26-294724","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1087940/000119312526294724/ownership.xml","form_type":"4"}},{"id":747836,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T21:56:50.000Z","date":"2026-06-04","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares subject to this option are fully vested."}],"balance_after":0,"derivative":{"exercise_price":1.04,"expiration_date":"2026-06-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001754045-26-000006","document":"form4-06052026_090646.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000006/form4-06052026_090646.xml","form_type":"4"}},{"id":747835,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-05T21:56:50.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":4104,"price":34.67,"value":142285.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $34.49 to $35.05, inclusive."}],"balance_after":211930,"source":{"system":"sec-edgar","filing":"0001754045-26-000006","document":"form4-06052026_090646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000006/form4-06052026_090646.xml","form_type":"4"}},{"id":747834,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-05T21:56:50.000Z","date":"2026-06-04","kind":"sale","planned":true,"acquired":false,"shares":25896,"price":34.01,"value":880722.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $33.49 to $34.48, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in these footnotes."}],"balance_after":216034,"source":{"system":"sec-edgar","filing":"0001754045-26-000006","document":"form4-06052026_090646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000006/form4-06052026_090646.xml","form_type":"4"}},{"id":747833,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-06-05T21:56:50.000Z","date":"2026-06-04","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":1.04,"value":31200.0,"ownership":{"direct":true},"balance_after":241930,"source":{"system":"sec-edgar","filing":"0001754045-26-000006","document":"form4-06052026_090646.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000006/form4-06052026_090646.xml","form_type":"4"}},{"id":806978,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-16T21:00:16.000Z","date":"2026-04-15","kind":"exercise","planned":false,"acquired":false,"shares":28614,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option are fully vested."}],"balance_after":30000,"derivative":{"exercise_price":1.04,"expiration_date":"2026-06-22","underlying":"Common Stock","underlying_shares":28614},"source":{"system":"sec-edgar","filing":"0001754045-26-000004","document":"form4-04162026_090412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000004/form4-04162026_090412.xml","form_type":"4"}},{"id":806977,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-16T21:00:16.000Z","date":"2026-04-15","kind":"exercise","planned":false,"acquired":true,"shares":28614,"price":1.04,"value":29758.56,"ownership":{"direct":true},"balance_after":211930,"source":{"system":"sec-edgar","filing":"0001754045-26-000004","document":"form4-04162026_090412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000004/form4-04162026_090412.xml","form_type":"4"}},{"id":819430,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-03T00:26:22.000Z","date":"2026-04-02","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares subject to this option are fully vested."}],"balance_after":58614,"derivative":{"exercise_price":1.04,"expiration_date":"2026-06-22","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001754045-26-000002","document":"form4-04032026_120417.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000002/form4-04032026_120417.xml","form_type":"4"}},{"id":819429,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-03T00:26:22.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":600,"price":41.77,"value":25062.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $41.69 to $41.91, inclusive."}],"balance_after":183316,"source":{"system":"sec-edgar","filing":"0001754045-26-000002","document":"form4-04032026_120417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000002/form4-04032026_120417.xml","form_type":"4"}},{"id":819428,"issuer":{"id":4388,"kind":"organization","name":"Kodiak Sciences Inc."},"owners":[{"id":29751,"kind":"person","name":"BORGESON JOHN A.","position":1,"cik":"0001754045","reported_name":"BORGESON JOHN A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-04-03T00:26:22.000Z","date":"2026-04-02","kind":"sale","planned":true,"acquired":false,"shares":4231,"price":40.88,"value":172963.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 29, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $40.68 to $41.67, inclusive."}],"balance_after":183916,"source":{"system":"sec-edgar","filing":"0001754045-26-000002","document":"form4-04032026_120417.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1468748/000175404526000002/form4-04032026_120417.xml","form_type":"4"}}],"next_cursor":"2026-04-03T00:26:22.000000Z,819428"}